{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:03:19Z","timestamp":1762779799330,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21372110","21672093"],"award-info":[{"award-number":["21372110","21672093"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.bmcl.2019.01.034","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T11:33:35Z","timestamp":1548848015000},"page":"694-699","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors"],"prefix":"10.1016","volume":"29","author":[{"given":"You-Zhen","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Bo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yan","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Yuan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2019.01.034_b0005","first-page":"60","article-title":"The aurora kinase family in cell division and cancer","volume":"1786","author":"Vader","year":"2008","journal-title":"BBA Rev on Cancer"},{"key":"10.1016\/j.bmcl.2019.01.034_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.MCR-06-0208","article-title":"Roles of aurora kinases in mitosis and tumorigenesis","volume":"5","author":"Fu","year":"2007","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bmcl.2019.01.034_b0015","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/med.21399","article-title":"Aurora-A kinase: a potent oncogene and target for cancer therapy","volume":"36","author":"Yan","year":"2016","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2019.01.034_b0020","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4161\/cc.9.7.11177","article-title":"Centromere localization of incenp-Aurora B is sufficient to support spindle checkpoint function","volume":"9","author":"Becker","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmcl.2019.01.034_b0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/cm.20039","article-title":"Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells","volume":"59","author":"Sasai","year":"2010","journal-title":"Cell Motil Cytoskel"},{"key":"10.1016\/j.bmcl.2019.01.034_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2017.08.045","article-title":"A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies","volume":"140","author":"Borisa","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2019.01.034_b0040","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1021\/jm901913s","article-title":"Discovery of N-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine Aurora kinase inhibitors","volume":"53","author":"Wang","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0045","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1021\/acs.jmedchem.5b00183","article-title":"Discovery of N-(4-(3-(2-amino pyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1- amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell lines","volume":"58","author":"Geunsmeyer","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0050","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1021\/jm049076m","article-title":"Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition","volume":"48","author":"Fancelli","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2019.01.034_b0060","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/ml500409n","article-title":"Mln8054 and alisertib (mln8237): discovery of selective oral Aurora A inhibitors","volume":"6","author":"Sells","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.01.034_b0065","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.4161\/cc.6.22.4940","article-title":"VX-680 inhibits Aurora A and Aurora B kinase activity in human cells","volume":"6","author":"Tyler","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmcl.2019.01.034_b0070","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1021\/jm100262j","article-title":"Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora Kinases: Lead optimization studies toward the identification of an orally bioavailable preclinical development candidate","volume":"53","author":"Bavetsias","year":"2010","journal-title":"J Med Chem"},{"year":"2008","series-title":"Nitroxides: applications in chemistry, biomedicine, and materials science","author":"Likhtenshtein","key":"10.1016\/j.bmcl.2019.01.034_b0075"},{"key":"10.1016\/j.bmcl.2019.01.034_b0080","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1126\/science.291.5502.266","article-title":"Freed, Electron spin resonance in studies of membranes and proteins","volume":"291","author":"Borbat","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2019.01.034_b0085","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0959-8049(02)00742-6","article-title":"Study of in vitro and in vivo effects of the piperidine nitroxide Tempol-a potential new therapeutic agent for gliomas","volume":"39","author":"Gariboldi","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2019.01.034_b0090","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1021\/jm061481l","article-title":"Development of molecular probes for second-site screening and design of protein tyrosine phosphatase inhibitors","volume":"50","author":"Vazquez","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2012.01.021","article-title":"Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethyl piperidine-N-oxyl as potential epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and EPR bio-probe agents","volume":"49","author":"Li","year":"2012","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0100","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1016\/j.bmcl.2008.05.051","article-title":"Carbonic anhydrase inhibitors: Design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes","volume":"18","author":"Cecchi","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2019.01.034_b0105","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1016\/j.bmc.2005.12.025","article-title":"Synthesis and biological evaluation of new spin-labeled derivatives of podophyllotoxin","volume":"14","author":"Jin","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0110","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.ejmech.2009.12.032","article-title":"First synthesis and biological evaluation of novel spin-labeled derivatives of deoxypodophyllotoxin","volume":"45","author":"Zhang","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bmc.2018.11.006","article-title":"Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors","volume":"27","author":"Sang","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejmech.2015.03.044","article-title":"Synthesis and biological evaluation of 2,4-diaminepyrimides as selective Aurora A kinase inhibitors","volume":"95","author":"Qin","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0125","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1021\/jm061335f","article-title":"Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase","volume":"50","author":"Mortlock","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0130","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/1087057106296047","article-title":"Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors","volume":"12","author":"Kashem","year":"2007","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmcl.2019.01.034_b0135","doi-asserted-by":"crossref","first-page":"15440","DOI":"10.1073\/pnas.202606599","article-title":"Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A","volume":"99","author":"Littlepage","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2019.01.034_b0140","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1083\/jcb.200204155","article-title":"Human TPX2 is required for targeting Aurora-A kinase to the spindle","volume":"158","author":"Kufer","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bmcl.2019.01.034_b0145","first-page":"5168","article-title":"Increased mitotic phosphorylation of histone h3 attributable to AIM-1\/Aurora-B over expression contributes to chromosome number instability","volume":"62","author":"Ota","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2019.01.034_b0150","series-title":"Aurora kinases and their inhibitors: More than one target and one drug, targeted therapies in cancer","first-page":"54","author":"Carpinelli","year":"2008"},{"key":"10.1016\/j.bmcl.2019.01.034_b0155","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1016\/j.bmc.2017.05.028","article-title":"The tobacco cembranoid (1S,2E,4S,7E,11E)-2,7,11-cembratriene-4,6-diol as a novel angiogenesis inhibitory lead for the control of breast malignancies","volume":"25","author":"Hailat","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2019.01.034_b0160","first-page":"442","article-title":"The pymol molecular graphics system","volume":"30","author":"Delano","year":"2014","journal-title":"DeLano Scientific, Palo Alto, CA, USA"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19300551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X19300551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:26:16Z","timestamp":1760772376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X19300551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0960894X19300551"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.01.034","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2019.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}